<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01182298</url>
  </required_header>
  <id_info>
    <org_study_id>100159</org_study_id>
    <secondary_id>10-I-0159</secondary_id>
    <nct_id>NCT01182298</nct_id>
  </id_info>
  <brief_title>Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection</brief_title>
  <acronym>LATHCV</acronym>
  <official_title>Study to Evaluate the Genetic, Epigenetic, and Proteomic Expression in Latino Participants With and Without HIV Coinfection Receiving Treatment for Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FDI Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      -  Peginterferon alfa-2a has been approved by the U.S. Food and Drug Administration (FDA)&#xD;
           to treat adults with chronic hepatitis C virus (HCV) infection with liver disease who&#xD;
           have not been previously treated with interferon-alpha drugs (which improve immune&#xD;
           system response to infection). Ribavirin has been approved by the FDA and is usually&#xD;
           given in combination with interferon drugs such as peginterferon alfa-2a for treatment&#xD;
           of chronic HCV.&#xD;
&#xD;
        -  Recent research shows that Latino whites do not respond as well to treatment with&#xD;
           peginterferon alfa-2a and ribavirin as non-Latino whites. Various factors such as&#xD;
           excessive weight, gender, and insulin resistance were evaluated to explain this&#xD;
           difference, but research suggests that underlying factors related to Latino or&#xD;
           non-Latino background, possibly genetic and immune differences, may be affecting the&#xD;
           response to HCV infection and treatment. However, more research is needed on the&#xD;
           effectiveness of peginterferon and ribavirin in Latino subjects with HCV, and with&#xD;
           combined and human immunodeficiency virus (HIV) co-infection.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To evaluate the safety, effectiveness, and viral response of peginterferon alfa-2a and&#xD;
      ribavirin therapy for chronic hepatitis C in Latino participants with and without HIV&#xD;
      co-infection.&#xD;
&#xD;
      This is an observational study. The observed treatment is received and managed through their&#xD;
      primary care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis C is a major health problem affecting 100- 300 million individuals worldwide.&#xD;
      Chronic hepatitis C virus (HCV) infection leads to cirrhosis in approximately 20% of subjects&#xD;
      over a period of 1-20 years. Hepatitis C is now the most common indication for liver&#xD;
      transplantation in the United States. infection occurs in one-third of all HIV-infected&#xD;
      individuals, and the natural history among HIV-1 infected individuals demonstrates higher&#xD;
      levels of HCV viremia, faster rates of progression and cirrhosis. There have been very few&#xD;
      studies addressing the lower therapeutic response rates in minorities outside of African&#xD;
      Americans. A recent study showed that Latino white subjects respond less effectively (34%)&#xD;
      than non Latino white subjects (49%) given the same treatment even after adjusting for&#xD;
      various important factors. As the current landscape for treatment of HCV changes, it would be&#xD;
      important to evaluate factors responsible for therapeutic response in Latino patients.&#xD;
&#xD;
      This is a study to address the genetic, epigenetic, and proteomic expression during therapy&#xD;
      for chronic hepatitis C in Latino participants with and without HIV co-infection. One hundred&#xD;
      Latino participants who have evidence of chronic hepatitis C with and without HIV who are&#xD;
      receiving treatment for HCV will be enrolled. The results of this study will enable us to&#xD;
      explore reasons for the differential therapeutic response rates with Hepatitis C treatment in&#xD;
      Latino participants with and without HIV coinfection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    small number of patients enrolled&#xD;
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Median Log Change in HCV RNA Levels on Day 7</measure>
    <time_frame>first 7 days</time_frame>
    <description>The primary end point of this study is the the log change in HCV RNA levels on Day 7</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Hepatitis C</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Hepatitis C</arm_group_label>
    <description>latino participants with Hepatitis C</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and serum storage.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        latino with or without HIV infection undergoing Hepatitis C treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        A subject must satisfy all of the following criteria to be eligible to participate in this&#xD;
        study:&#xD;
&#xD;
          1. Latino ethnicity. Latino ethnic background will be defined as a geographic,&#xD;
             historical, and cultural heritage shared among persons from Spanish-speaking countries&#xD;
             in South and Central America, Mexico, and the Caribbean. Both parents and all&#xD;
             grandparents of the participant have to be Latino, with Spanish as the primary&#xD;
             language. Participants have to be white; native aboriginal Indians, Asians, and blacks&#xD;
             will be excluded.&#xD;
&#xD;
          2. Age greater than or equal to 18 years.&#xD;
&#xD;
          3. Documentation of hepatitis C infection by demonstration of a positive test for&#xD;
             hepatitis C antibody and HCV RNA level of greater than or equal to 2,000 IU/mL.&#xD;
&#xD;
          4. Documentation of HIV-1 infection in the second group of co-infected participants by a&#xD;
             licensed enzyme-linked immunosorbent assay and confirmed by a Western blot or by HIV&#xD;
             polymerase chain reaction positive.&#xD;
&#xD;
          5. Participants with HIV: CD4+ cell counts greater than or equal to 100 cells/mm(3) or&#xD;
             CD4+ cell percentage greater than or equal to 14%.&#xD;
&#xD;
          6. Ability to provide informed consent and willingness to comply with the study&#xD;
             requirements, storage of blood samples and clinic policies.&#xD;
&#xD;
          7. Participants must have a primary care physician managing medical problems.&#xD;
&#xD;
          8. For HIV infected participants, care provided by a primary physician must be consistent&#xD;
             with the current DHHS guidelines. For those on therapy, HAART will be provided by&#xD;
             their physician.&#xD;
&#xD;
          9. Willing to undergo genetic testing&#xD;
&#xD;
         10. About to start HCV treatment (with or without direct acting agents DAAs)&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        A subject will be ineligible to participate in this study if any of the following criteria&#xD;
        are met:&#xD;
&#xD;
          1. Unable to comply with research study visits&#xD;
&#xD;
          2. Have any condition that the investigator considers a contraindication to study&#xD;
             participation.&#xD;
&#xD;
          3. Pregnant or breastfeeding women.&#xD;
&#xD;
          4. Patients with poor venous access&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyamasundaran Kottilil, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis. 2003 Feb;7(1):261-87. Review.</citation>
    <PMID>12691470</PMID>
  </reference>
  <reference>
    <citation>Engels EA, Chatterjee N, Cerhan JR, Davis S, Cozen W, Severson RK, Whitby D, Colt JS, Hartge P. Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study. Int J Cancer. 2004 Aug 10;111(1):76-80.</citation>
    <PMID>15185346</PMID>
  </reference>
  <reference>
    <citation>Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997 Mar 22;349(9055):825-32.</citation>
    <PMID>9121257</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>August 13, 2010</study_first_submitted>
  <study_first_submitted_qc>August 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2010</study_first_posted>
  <results_first_submitted>April 23, 2014</results_first_submitted>
  <results_first_submitted_qc>September 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 2, 2014</results_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Latino</keyword>
  <keyword>HCV</keyword>
  <keyword>pegIFN</keyword>
  <keyword>Viral Kinetics</keyword>
  <keyword>IL-28 Haplotype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PegIFN and Ribavirin</title>
          <description>Latino Patients with hepatitis C receiving weekly pegIFN and ribavirin.&#xD;
This is an observational study. The observed treatment is received and managed through their primary care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>LATINO PARTICIPANTS WITH hepatitis C</population>
      <group_list>
        <group group_id="B1">
          <title>Standard</title>
          <description>HCV INFECTED LATINO ARTICIPANTS</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Log Change in HCV RNA Levels on Day 7</title>
        <description>The primary end point of this study is the the log change in HCV RNA levels on Day 7</description>
        <time_frame>first 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hepatitis C</title>
            <description>latino participants with Hepatitis C</description>
          </group>
        </group_list>
        <measure>
          <title>Median Log Change in HCV RNA Levels on Day 7</title>
          <description>The primary end point of this study is the the log change in HCV RNA levels on Day 7</description>
          <units>log IU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to the change in the standard of care treatment of HCV, it became difficult to recruit patients to receive IFN based therapy with the prospects of IFN free treatment being available sooner. Numbers are insufficient to generate results.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard</title>
          <description>Patients receiving weekly peg interferon and ribavirin for hCV treatment were studied This is an observational study. The observed treatment is received and managed through their primary care.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to small numbers of subjects enrolled as the options for HCV treatment changed significantly since the start of the study planning.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Shyam Kottilil</name_or_title>
      <organization>NIAID</organization>
      <email>Skottilil@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

